Agenus Q1 Results: Revenue Misses Estimates, Net Income Turns Positive as BATTMAN Trial Advances

Agenus Inc. (NASDAQ: AGEN), a clinical-stage immuno-oncology company focused on cancer treatments, reported first-quarter 2026 financial results and provided an update on its lead botensilimab plus balstilimab, or BOT+BAL, program.

For the quarter ended March 31, 2026, Agenus reported total revenue of $33.7 million, compared with $24.1 million in the same period last year. The result was below the widely cited analyst revenue estimate of $129.5 million, indicating a significant revenue miss versus expectations. The company also reported net income of $39.2 million, compared with a net loss of $26.4 million in the first quarter of 2025. 

Agenus continued to advance its lead clinical program during the quarter. The global Phase 3 BATTMAN trial began enrolling patients in April 2026 and is evaluating BOT+BAL versus best supportive care in patients with refractory, unresectable microsatellite stable/mismatch repair proficient metastatic colorectal cancer. The trial is led by the Canadian Cancer Trials Group and includes participating networks in Canada, France, Australia and New Zealand.

The company also highlighted its strategic collaboration with Zydus Lifesciences, which closed in January 2026. The transaction provided $91 million of upfront capital, including $75 million in cash consideration for the transfer of biologics manufacturing facilities and a $16 million equity investment, while also securing dedicated U.S. biologics manufacturing capacity for BOT+BAL development and potential future commercialization.

From a liquidity perspective, Agenus reported $35.0 million in cash and cash equivalents as of March 31, 2026, compared with $3.0 million at the end of 2025. Its current ratio of about 0.41 suggests limited short-term financial flexibility, although the company noted that first-quarter cash payments included substantial Zydus-related closing costs and supply-build expenses that it does not view as representative of recurring operating expenses.